Abstract
The versatility of three-dimensional printed
pharmaceuticals, relative to traditionally
manufactured ones, could be leveraged
for personalized treatment at the point of
care, as well as being integrated into massmanufacturing
pipelines. Improvements
in quality control and collaboration with
regulatory bodies will pave the way to
large-scale clinical translation.
pharmaceuticals, relative to traditionally
manufactured ones, could be leveraged
for personalized treatment at the point of
care, as well as being integrated into massmanufacturing
pipelines. Improvements
in quality control and collaboration with
regulatory bodies will pave the way to
large-scale clinical translation.
| Original language | English |
|---|---|
| Pages (from-to) | 801-803 |
| Number of pages | 3 |
| Journal | Nature Reviews Bioengineering |
| Volume | 2 |
| Early online date | 1 Jul 2024 |
| DOIs |
|
| Publication status | Published - 30 Oct 2024 |